ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Factors Associated With Fatality Due to Avian Influenza A(H7N9) Infection in China.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza.iScience · 2026Article
- Development and Validation of a Nomogram to Predict Respiratory Failure With Influenza.Immunity, inflammation and disease · 2026Article
- Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza.Nature communications · 2026Article
- UMPlex™: a targeted next-generation sequencing primer design workflow.Virology journal · 2025Article
- Clinical Characteristics and Predicting Disease Severity in Chlamydia psittaci Infection Based on Metagenomic Next-Generation Sequencing.Infection and drug resistance · 2025Article
- Risk factors for secondary infection after liver failure and effect of comprehensive nursing intervention.World journal of clinical cases · 2024Article
- Analysis of data from two influenza surveillance hospitals in Zhejiang province, China, for the period 2018-2022.PloS one · 2024Article
- Annual incidence and fatality rates of notifiable infectious diseases in southeast China from 1950 to 2022 and relationship to socioeconomic development.Journal of global health · 2023Article
- Risk factors for in-hospital mortality and secondary bacterial pneumonia among hospitalized adult patients with community-acquired influenza: a large retrospective cohort study.Antimicrobial resistance and infection control · 2023Article
- Review
- NS2 is a key determinant of compatibility in reassortant avian influenza virus with heterologous H7N9-derived NS segment.Virus research · 2023Article
- Endothelial Glycocalyx Injury in SARS-CoV-2 Infection: Molecular Mechanisms and Potential Targeted Therapy.Mediators of inflammation · 2023Review
- Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Nosocomial Infections in Nonsurgical Patients Undergoing Extracorporeal Membrane Oxygenation: A Retrospective Analysis in a Chinese Hospital.Infection and drug resistance · 2022Article
- Spatio-temporal spread and evolution of influenza A (H7N9) viruses.Frontiers in microbiology · 2022Article
- Secondary Bacterial Infections in Critical Ill Patients With Coronavirus Disease 2019.Open forum infectious diseases · 2020Article
- Novel Avian Influenza A Virus Infections of Humans.Infectious disease clinics of North America · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundThe high case fatality rate of influenza A(H7N9)-infected patients has been a major clinical concern.
methodsTo identify the common causes of death due to H7N9 as well as identify risk factors associated with the high inpatient mortality, we retrospectively collected clinical treatment information from 350 hospitalized human cases of H7N9 virus in mainland China during 2013-2017, of which 109 (31.1%) had died, and systematically analyzed the patients' clinical characteristics and risk factors for death.
resultsThe median age at time of infection was 57 years, whereas the median age at time of death was 61 years, significantly older than those who survived. In contrast to previous studies, we found nosocomial infections comprising Acinetobacter baumannii and Klebsiella most commonly associated with secondary bacterial infections, which was likely due to the high utilization of supportive therapies, including mechanical ventilation (52.6%), extracorporeal membrane oxygenation (14%), continuous renal replacement therapy (19.1%), and artificial liver therapy (9.7%). Age, time from illness onset to antiviral therapy initiation, and secondary bacterial infection were independent risk factors for death. Age >65 years, secondary bacterial infections, and initiation of neuraminidase-inhibitor therapy after 5 days from symptom onset were associated with increased risk of death.
conclusionsDeath among H7N9 virus-infected patients occurred rapidly after hospital admission, especially among older patients, followed by severe hypoxemia and multisystem organ failure. Our results show that early neuraminidase-inhibitor therapy and reduction of secondary bacterial infections can help reduce mortality.Characterization of 350 hospitalized avian influenza A(H7N9)-infected patients in China shows that age >65 years, secondary bacterial infections, and initiation of neuraminidase-inhibitor therapy after 5 days from symptom onset were associated with increased risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.